Lilly pursues new Cymbalta approval

What do you do with a booming antidepressant? Broaden its scope, of course. Eli Lilly has filed for FDA approval to sell Cymbalta as a fibromyalgia remedy. It's already marketed for use against general anxiety and nerve pain, in addition to depression.

Lilly announced its supplemental drug app with news of a study that found that fibromyalgia patients taking Cymbalta felt less pain than those taking placebo. The study subjects included patients with depression and those without. Already, Cymbalta has been a hot performer for Lilly this year. First-quarter sales of the drug were up almost 90 percent over the same period last year, to $41.8 million, and second quarter sales reached $519.5 million, at least in part because of an aggressive direct-to-consumer campaign begun last summer. If approved for fibromyalgia, Cymbalta would find a broad new market: an estimated 3 to 6 million Americans have the disease, according to the American College of Rheumatology.

- check out the release
- read the RTT News report

Related Articles:
Pfizer touts blockbuster drug for fibromyalgia. Report
Forest Labs reports Phase III failure for fibromyalgia drug. Report
FDA hands out two key regulatory approvals. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.